scholarly journals Radiation doses in prostatic artery embolization for benign prostatic hypertrophy: a single-institution series and meta-analysis

2017 ◽  
Vol 28 (2) ◽  
pp. S149 ◽  
Author(s):  
M Tanaka ◽  
E Lacayo ◽  
J Katrivesis ◽  
J Spies ◽  
A Kim
2016 ◽  
Vol 27 (11) ◽  
pp. 1686-1697.e8 ◽  
Author(s):  
Andre Uflacker ◽  
Ziv J Haskal ◽  
Tiago Bilhim ◽  
James Patrie ◽  
Timothy Huber ◽  
...  

2019 ◽  
Vol 185 (2) ◽  
pp. 196-200
Author(s):  
W J Garzón ◽  
H J Khoury

Abstract The objective of this study was to assess the radiation doses received by anaesthetists from prostatic artery embolization (PAE) procedures. Ten PAE procedures conducted in a reference hospital in the city of Recife, Brazil were investigated. Occupational dosimetry was performed using thermoluminescent dosemeters which were located next to the eyes, close to the thyroid (over the shielding), on the thorax (under the apron), on the wrist and on the feet of the physician’s body. The results showed that the anaesthetist’s feet received the highest doses followed by the eyes and the hands. In some complex PAE procedures the doses received by anaesthetists on the lens of the eyes and the effective dose were higher than those received by the main operator due to the anaesthetist’s close position to the patient’s table and the use of oblique projections. The personal dose equivalent Hp(3) per procedure for the anaesthetist’s right eyebrow ranged from 20.2 μSv to 568.3 μSv. This result shows that anaesthetists assisting PAE procedures can exceeds the annual eye lens dose limit of 20 mSv recommended by the ICRP with only one procedure per week if radiation protection measures are not implemented during procedures.


2019 ◽  
Vol 8 (6) ◽  
pp. 205846011984606 ◽  
Author(s):  
Charles R Tapping ◽  
Jeremy Crew ◽  
Andrew Proteroe ◽  
Phil Boardman

Prostate artery embolization (PAE) has been shown to be beneficial in treating men with benign prostatic hypertrophy (BPH). Here we describe treating four patients with prostate cancer (two with organ-confined and two with metastatic prostate cancer) with prostatic bleeding with PAE. Patients had other causes of hematuria excluded and were followed up at 3, 12, and 18 months after PAE. All four cases were technically successful and all cases of hematuria had resolved by the three-month follow-up (100%). There was one case of recurrence at 13 months after PAE which was successfully treated. PAE is useful for controlling significant prostatic bleeding in patients with prostate cancer and improves quality of life. Patients may, however, need repeated treatments to control the bleeding.


Sign in / Sign up

Export Citation Format

Share Document